Search Result

Isoforms Recommended:	ATM

Results for "

Atm

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ATM/ATR (52) Ack1 (1) Akt (1) Amyloid-β (3) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (21) Autophagy (1) Bacterial (3) Bcl-2 Family (1) Beta-lactamase (1) Biochemical Assay Reagents (1) c-Met/HGFR (1) Caspase (2) CDK (4) Checkpoint Kinase (Chk) (5) Choline Kinase (1) Cholinesterase (ChE) (1) CMV (3) DNA-PK (1) DNA/RNA Synthesis (9) Drug Derivative (1) Dystrophin (1) E1/E2/E3 Enzyme (1) EGFR (1) Endonuclease (1) ERK (1) Ferroptosis (1) FLAP (1) Fungal (1) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HSV (3) IAP (1) Isotope-Labeled Compounds (1) JNK (1) Ligands for Target Protein for PROTAC (2) MDM-2/p53 (4) MicroRNA (1) Mitosis (1) Molecular Glues (1) mTOR (5) Myosin (3) NF-κB (1) Notch (1) Nucleoside Antimetabolite/Analog (3) p38 MAPK (1) PARP (2) PD-1/PD-L1 (2) PDGFR (1) Phosphatase (2) PI3K (2) PROTACs (4) PTEN (1) RAD51 (1) Reactive Oxygen Species (ROS) (1) Reference Standards (5) Small Interfering RNA (siRNA) (3) STING (2) TNF Receptor (1) Topoisomerase (1) VEGFR (2) γ-secretase (1)
By Research Areas:	Cancer (67) Cardiovascular Disease (2) Infection (5) Inflammation/Immunology (6) Metabolic Disease (2) Neurological Disease (6)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: ATM/ATR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0097

Floxuridine 10+ Cited Publications 5-Fluorouracil 2'-deoxyriboside	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-12016

KU-55933 Maximum Cited Publications 62 Publications Verification	ATM/ATR Autophagy	Cancer
KU-55933 is a potent *ATM* inhibitor with an IC₅₀ and K_i of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

HY-109566

AZD1390 5+ Cited Publications	ATM/ATR	Inflammation/Immunology Cancer
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant *ATM* inhibitor with an IC₅₀ of 0.78 nM in cell .

HY-12061

KU-60019 25+ Cited Publications	ATM/ATR	Cancer
KU-60019 is an improved *ATM* kinase-specific inhibitor with IC₅₀ of 6.3 nM.

HY-139609

Camonsertib 2 Publications Verification RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-100016

AZD0156 10+ Cited Publications	ATM/ATR Apoptosis	Cancer
AZD0156 is a potent, selective and orally active *ATM* inhibitor with an IC₅₀ of 0.58 nM. AZD0156 inhibits the *ATM*-mediated signaling, prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis .

HY-19959

Mirin 5+ Cited Publications	ATM/ATR Apoptosis	Cancer
Mirin is a potent Mre11-Rad50-Nbs1 (MRN) complex inhibitor. Mirin prevents MRN-dependent activation of ATM (IC₅₀=12 μM) without affecting ATM protein kinase activity, and it inhibits Mre11-associated exonuclease activity. Mirin abolishes the G2/M checkpoint and homology-dependent repair in mammalian cells. Mirin prevents ATM activation in response to DNA double-strand breaks (DSBs) and blocks homology-directed repair (HDR) in mammalian cells .

HY-157941

ART0380	ATM/ATR Checkpoint Kinase (Chk) DNA/RNA Synthesis	Cancer
ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC₅₀ of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .

HY-123834

FEN1-IN-1 5+ Cited Publications	FLAP ATM/ATR	Cancer
FEN1-IN-1 (compound 1) is a small molecule flap endonuclease 1 (FEN1) inhibitor with antitumor activity. FEN1-IN-1 binds to the active site of FEN1 and partly achieves inhibition by the co-ordination of Mg ²⁺ ions. FEN1-IN-1 initiaties a DNA damage response and activates the ATM checkpoint signalling pathway, the phosphorylation of histone H2AX and the ubiquitination of FANCD2 in mammalian cells. FEN1-IN-1 is promising for research of cancers .

HY-162472

XRD-0394	ATM/ATR DNA-PK	Cancer
XRD-0394 is a potent and orally active dual ATM and DNA-PKcs inhibitor with IC₅₀s of 0.39 nM and 0.89 nM, respectively. XRD-0394 shows selectivity over other PIKK and PI3K family members. XRD-0394 significantly enhances tumor cell killing in vitro and in vivo under therapeutic ionizing radiation conditions. XRD-0394 can potentiate the effects of PARP and topoisomerase I inhibitors in vitro .

HY-171124

Tilatamig samrotecan AZD9592	Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis	Cancer
Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .

HY-16705

BRD4770 5 Publications Verification	Histone Methyltransferase	Cancer
BRD4770 is a histone methyltransferase G9a inhibitor. BRD4770 reduces di- and trimethylation of lysine 9 on histone H3 (H3K9) with an EC₅₀ of 5 μM, and has less or little effect toward H3K27me3, H3K36me3, H3K4me3, and H3K79me3. BRD4770 can activate the ataxia telangiectasia mutated (ATM) pathway and induce cell senescence .

HY-P991049

Atrosimab Atm-001	TNF Receptor	Metabolic Disease Inflammation/Immunology
Atrosimab is an Fv-Fc1K fusion protein with an EC₅₀ value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .

HY-15520

CGK733 5+ Cited Publications	ATM/ATR	Cancer
CGK733 is a potent *ATM/ATR* inhibitor, used for the research of cancer.

HY-N0245

Theaflavin-3-gallate	Apoptosis MDM-2/p53 ATM/ATR Checkpoint Kinase (Chk)	Cancer
Theaflavin-3-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner. Theaflavin-3-gallate induces apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells through p53-dependent pathways. Theaflavin-3-gallate induces DNA damage through *ATM/Chk/p53* pathway .

HY-150617

Lartesertib 1 Publications Verification M4076; Atm Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase *ATM* with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-117693

(E/Z)-Mirin 5+ Cited Publications	ATM/ATR	Cancer
(E/Z)-Mirin is a mixture of (E)-Mirin and Mirin ((Z)-Mirin) (HY-19959) configurations. Among them, Mirin is an inhibitor of MRN (Mre11-Rad50-Nbs1). Mirin prevents MRN-dependent ATM activation without affecting ATM protein kinase activity .

HY-15290

AIM-100 4 Publications Verification	Ack1	Cancer
AIM-100 is a potent and selective Ack1 inhibitor with an IC₅₀ of 21.58 nM. AIM-100 also inhibits Tyr ²⁶⁷ phosphorylation. AIM-100 does not inhibits other kinases including PI3-kinase and AKT subfamily members. AIM-100 has an anticancer effect .

HY-162002

WSD0628	ATM/ATR	Cancer
WSD0628 is a brain penetrant and potent *ATM* inhibitor with profound radiosensitizing effect .

HY-103241

Ro 90-7501 3 Publications Verification	Amyloid-β ATM/ATR Phosphatase Apoptosis	Neurological Disease Cancer
Ro 90-7501 is an amyloid β₄₂ (Aβ₄₂) fibril assembly inhibitor that reduces Aβ₄₂-induced cytotoxicity (EC₅₀ of 2 μM). Ro 90-7501 inhibits *ATM* phosphorylation and DNA repair. RO 90-7501 selectively enhances toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) ligand-induced IFN-β gene expression and antiviral response . Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner . Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells .

HY-112198

AZ31	ATM/ATR	Cancer
AZ31 is a a potent, highly selective, and orally active *ATM* inhibitor with an IC₅₀ of <1.2 nM for ATM enzyme, and an IC₅₀ of 46 nM for ATM in cell. AZ31 shows excellent selectivity over ATR (>500-fold) and excellent PIKK-family selectivity and pan-kinase selectivity. AZ31 is a potent radiosensitizer in vitro, it can be used for the research of cancer .

HY-161615

PROTAC ATR degrader-2	PROTACs ATM/ATR Apoptosis	Inflammation/Immunology Cancer
PROTAC ATR degrader-2 is a selective ATR PROTAC degrader. PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC₅₀ values of 22.9 nM and 34.5 nM, respectively. PROTAC ATR degrader-2 has an IC₅₀ of 29.6 nM against ATR, and its IC₅₀ values against ATM and PI3K are both greater than 2000 nM. PROTAC ATR degrader-2 induces apoptosis, DNA damage, and upregulates p53 expression. PROTAC ATR degrader-2 inhibits cancer cell proliferation through the kinase-independent function of ATR protein. PROTAC ATR degrader-2 is applicable to research related to acute myeloid leukemia .

HY-163944

LL-K12-18	DNA/RNA Synthesis Molecular Glues CDK Apoptosis RAD51 ATM/ATR PARP	Cancer
LL-K12-18 is a CDK12 kinase inhibitor and a dual-site molecular glue. LL-K12-18 inhibits human CDK12 with an IC₅₀ value of 283.9 nM, and selectively degrades cyclin K via the ubiquitin-proteasome system by stabilizing the CDK12-DDB1 complex. LL-K12-18 downregulates DNA damage response genes, reduces the phosphorylation level of CTD Ser2 in RNA polymerase II, and modulates biomarkers such as ATM, RAD51, γ-H2AX and cleaved PARP, thereby effectively inducing apoptosis and inhibiting proliferation of breast cancer cells. LL-K12-18 exhibits high target selectivity and serves as a research tool for studies on triple-negative breast cancer .

HY-11002

CP-466722 4 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of *ATM, with an IC₅₀* of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-100948

ATM-3507	Myosin	Cancer
ATM-3507 is a potent tropomyosin inhibitor with IC₅₀s from 3.83-6.84 μM in human melanoma cell lines.

HY-160096

M3541	ATM/ATR	Cancer
M3541 is a potent, ATP-competitive and selective *ATM* inhibitor with an IC₅₀ of 0.25 nM. M3541 shows remarkable selectivity against other protein kinases. M3541 suppresses double-strand breaks (DSB) repair and has antitumor activities .

HY-112305

AZ32	ATM/ATR	Cancer
AZ32 is an orally bioavailable and blood-brain barrier-penetrating *ATM* inhibitor with an IC₅₀ of <6.2 nM for ATM enzyme, and an IC₅₀ of 0.31 μM for ATM in cell.

HY-158345

*PROTAC ATM* degrader-1**	PROTACs ATM/ATR DNA/RNA Synthesis Apoptosis	Cancer
PROTAC ATM degrader-1 is a ATM PROTAC degrader with a K_D value of 1.17 nM. PROTAC ATM degrader-1 triggers DNA damage response, cell cycle arrest, and apoptosis in cancer cells via the ubiquitin-proteasome-dependent degradation pathway. PROTAC ATM degrader-1 can be used for research on colorectal cancer .

HY-157767

Abd110	PROTACs ATM/ATR	Cancer
Abd110 (compound 42i) is a Lenalidomide-based PROTAC ATR kinase degrader. Abd110 selectively decreases ATR and phospho-ATR without affecting related kinases ATM and DNA-PKcs .

HY-170844

MU147	Endonuclease	Cancer
MU147 is an MRE11 nuclease inhibitor and chemical probe with anticancer activity, which is lethal to Ehrlich ascites tumor cells both in vitro and in vivo. MU147 also eliminates the double-strand break repair mechanism dependent on the MRE11 nuclease activity without impairing the activation of ATM. MU147 also impairs the degradation of nascent strands of stalled replication FOX and selectively affects brca2-deficient cells .

HY-118911

ATM Inhibitor-10	ATM/ATR	Cancer
ATM Inhibitor-10 (compound 74), a 3-quinoline carboxamide, is a highly selective and orally active *ATM* inhibitor (IC₅₀: 0.6 nM). ATM Inhibitor-10 has anti-tumor activity in SW620 xenograft models. ATM Inhibitor-10 is synergistic with Top I inhibitors .

HY-144217

SKLB-197	ATM/ATR	Cancer
SKLB-197 showed an IC₅₀ value of 0.013 μM against ATR but very weak or no activity against other 402 protein kinases. It displayed potent antitumor activity against ATM-deficent tumors both in vitro and in vivo.

HY-119757

Tyrphostin AG1433 SU1433; AG1433	PDGFR VEGFR	Cancer
Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC₅₀s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .

HY-118921

Ovatodiolide	Apoptosis	Infection Inflammation/Immunology Cancer
Ovatodiolide is a compound that can be isolated from Anisomeles indica. Ovatodiolide has anti-bacterial and anti-inflammatory properties. Ovatodiolide also has anti-cancer activity that induces cell cycle G2/M arrest and apoptosis via a ROS-dependent ATM/ATR signaling pathways .

HY-B0097R

Floxuridine (Standard) 5-Fluorouracil 2'-deoxyriboside (Standard)	Reference Standards Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Bacterial CMV HSV Apoptosis	Infection Cancer
Floxuridine (Standard) is the analytical standard of Floxuridine. This product is intended for research and analytical applications. Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

HY-N11709

Theasaponin E1	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal	Infection Neurological Disease Metabolic Disease Cancer
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of *ATM* protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-18650

KU 59403 1 Publications Verification	ATM/ATR	Cancer
KU 59403 is a potent *ATM* inhibitor, with IC₅₀ values of 3 nM, 9.1 μM and 10 μM for ATM, DNA-PK and PI3K, respectively .

HY-19731

SID 3712249 MiR-544 Inhibitor 1	MicroRNA Apoptosis	Cancer
SID 3712249 (MiR-544 Inhibitor 1) is a miR-544 biogenesis inhibitor. SID 3712249 binds directly to the precursor miRNA. SID 3712249 blocks production of the mature microRNA and decreases miR-544, HIF-1α, and ATM transcripts. SID 3712249 can be used in the research of cancers, such as breast cancer .

HY-N6576

Hellebrigenin	p38 MAPK ERK JNK IAP PARP Apoptosis Caspase	Cancer
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the *ATM* pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .

HY-112614

ATM Inhibitor-1	ATM/ATR	Cancer
ATM Inhibitor-1 is a highly potent, selective and orally active *ATM* inhibitor, with an IC₅₀ of 0.7 nM, shows weak activity against mTOR (IC₅₀, 21 μM), DNAPK (IC₅₀, 2.8 μM), PI3Kα (IC₅₀, 3.8 μM), PI3Kβ (IC₅₀, 10.3 μM), PI3Kγ (IC₅₀, 3 μM) and PI3Kδ (IC₅₀, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity .

HY-142931

ATM-IN-1	ATM/ATR	Neurological Disease Cancer
ATM-IN-1 is a potent inhibitor of *ATM. ATM* is located mainly in the nucleus and microsomes and is involved in cell cycle progression and in the cell cycle checkpoint response to DNA damage. ATM-IN-1 has the potential for the research of cancer and neurology diseases (extracted from patent WO2021139814A1, compound 3) .

HY-162002A

(S)-WSD0628	ATM/ATR	Cancer
(S)-WSD0628 (Compound 28) is the S-isomer of WSD0628 (HY-162002). (S)-WSD0628 is the inhibitor for *ATM* that inhibits the phosphorylation of ATM in MCF-7 cell with IC₅₀ <100 nM. (S)-WSD0628 exhibits radiosensitizing activity. (S)-WSD0628 can cross blood-brain barrier .

HY-174989

ATM-IN-2	ATM/ATR Apoptosis	Cancer
ATM-IN-2 is a selective and orally active *ATM* inhibitor with an IC₅₀ of 4 nM. ATM-IN-2 exhibits excellent kinase selectivity (>700-fold over PIKK family members). ATM-IN-2 exerts its anti-tumor effect by inhibiting ATM phosphorylation and the downstream signaling pathways (p53, H2AX), and promotes cell apoptosis. ATM-IN-2 can be used for the study of chemosensitizer candidate such as colon cancer .

HY-100948B

ATM-3507 trihydrochloride	Myosin	Cancer
ATM-3507 trihydrochloride is a potent tropomyosin inhibitor with IC₅₀s from 3.83-6.84 μM in human melanoma cell lines.

HY-150617A

(Rac)-Lartesertib (Rac)-M4076; (Rac)-Atm Inhibitor-5	ATM/ATR STING PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
(Rac)-Lartesertib ((Rac)-M4076) is an isoform of Lartesertib (HY-150617). Lartesertib (M4076) is an inhibitor of the serine/threonine protein kinase *ATM* with high potency. Lartesertib can inhibit the growth of multiple hematopoietic cell lines. Additionally, when combined with the ATR inhibitor Tuvusertib (HY-111451), Lartesertib can promote the death of tumor cells, activate the immune signaling pathway, and exhibit anti-tumor activity .

HY-112477

Chk2-IN-1 Hymenialdisine analogue-1	Checkpoint Kinase (Chk) Choline Kinase	Cancer
Chk2-IN-1 (compound 1) is a potent and selective inhibitor of checkpoint kinase 2 (Chk2), with IC₅₀s of 13.5 nM and 220.4 nM for Chk2 and Chk1, respectively. Chk2-IN-1 can elicit a strong ataxia telangiectasia mutated (ATM)-dependent Chk2-mediated radioprotection effect .

HY-153787

ATM Inhibitor-6	ATM/ATR	Cancer
ATM inhibitor-6 (A-193) is a selective *ATM* kinase inhibitor. ATM inhibitor-6 can be used in cancer research .

HY-155090

ATM Inhibitor-8	ATM/ATR	Cancer
ATM Inhibitor-8 (Compound 10r) is a highly potent, selective and orally active *ATM* inhibitor,with an IC₅₀ of 1.15 nM. ATM Inhibitor-8 exhibits anti-tumor activity .

HY-136835

GJ071 oxalate	ATM/ATR	Neurological Disease
GJ071 oxalate induces ATM kinase activity in ataxia telangiectasia (A-T) cells carrying homozygous TGA or TAG stop codons .

HY-123359

RTC14	DNA/RNA Synthesis Dystrophin	Others
RTC14 is a read-through compound (RTC) that can induce ribosomes to bypass nonsense mutations in mRNA and allow the production of full-length functional proteins. RTC14 has the potential to be used in the research of various genetic disorders, such as nonsense mutations in the ataxia-telangiectasia mutated (ATM) gene and the dystrophin gene .

Cat. No.	Product Name

HY-L173

Anti-Ovarian Cancer Compound Library

2,817 compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 2,817 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L004

Cell Cycle/DNA Damage Compound Library

3,313 compounds

DNA is prone to numerous forms of damage that can injure cells and impair fitness. Cells have developed an array of mechanisms to repair these injuries. Proliferating cells are especially vulnerable to DNA damage due to the added demands of cellular growth and division. Cell cycle checkpoints represent integral components of DNA repair that coordinate cooperation between the machinery of the cell cycle and several biochemical pathways that respond to damage and restore DNA structure. By delaying progression through the cell cycle, checkpoints provide more time for repair before the critical phases of DNA replication, when the genome is replicated, and of mitosis, when the genome is segregated. Loss or attenuation of checkpoint function may increase spontaneous and induced gene mutations and chromosomal aberrations by reducing the efficiency of DNA repair.

MCE owns a unique collection of 3,313 cell cycle/DNA damage-related compounds which can be used in the research of the same.

Cat. No.	Product Name	Target	Research Area	Image

HY-P991049

Atrosimab Atm-001	TNF Receptor	Metabolic Disease Inflammation/Immunology
Atrosimab is an Fv-Fc1K fusion protein with an EC₅₀ value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0245

Theaflavin-3-gallate	Flavonoids Classification of Application Fields Flavanols Phenols Polyphenols Camellia sinensis (L.) O. Ktze. Plants Disease Research Fields Source Classification Theaceae Cancer	Apoptosis MDM-2/p53 ATM/ATR Checkpoint Kinase (Chk)
Theaflavin-3-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner. Theaflavin-3-gallate induces apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells through p53-dependent pathways. Theaflavin-3-gallate induces DNA damage through *ATM/Chk/p53* pathway .

HY-118921

Ovatodiolide	Terpenoids Labiatae Diterpenoids Plants Artemisia persica Boiss. Source Classification	Apoptosis
Ovatodiolide is a compound that can be isolated from Anisomeles indica. Ovatodiolide has anti-bacterial and anti-inflammatory properties. Ovatodiolide also has anti-cancer activity that induces cell cycle G2/M arrest and apoptosis via a ROS-dependent ATM/ATR signaling pathways .

HY-N11709

Theasaponin E1	Triterpenes Structural Classification Terpenoids Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Apoptosis VEGFR ATM/ATR PTEN Akt mTOR HIF/HIF Prolyl-Hydroxylase NF-κB Notch Cholinesterase (ChE) Amyloid-β γ-secretase Ferroptosis Fungal
Theasaponin E1 is an orally effective tea saponin. Theasaponin E1 inhibits the proliferation of cancer cells by activating apoptosis. Theasaponin E1 inhibits angiogenesis in ovarian cancer cells and HUVECs by reducing the expression of VEGF. Theasaponin E1 upregulates the phosphorylation level of *ATM* protein and the expression level of PTEN protein in cancer cells, decreases the phosphorylation levels of Akt, mTOR, p70S6K and 4E-BP1 proteins, downregulates the expression of HIF-1α and NF-κB, and reduces the protein expression of Notch ligands Dll4 and Jagged1. Theasaponin E1 exerts neuroprotective effects by inhibiting the activity of acetylcholinesterase, activating α-secretase and neprilysin, reducing the concentration of Aβ, and inhibiting the activities of β-secretase and γ-secretase. Theasaponin E1 exhibits toxic effects on cancer cells and quinone reductase-inducing activity, and inhibits tumor growth in vivo. Theasaponin E1 induces ferroptosis in Pomacea canaliculata by synergistically disrupting cholesterol homeostasis and sphingolipid metabolism. Theasaponin E1 possesses anti-biofilm activity against Candida albicans. Theasaponin E1 can be used in the research of ovarian cancer, obesity, Alzheimer's disease and fungal infections .

HY-N6576

Hellebrigenin	Animals Classification of Application Fields Disease Research Fields Steroids Source Classification Cancer	p38 MAPK ERK JNK IAP PARP Apoptosis Caspase
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the *ATM* pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .

HY-N0245R

Theaflavin-3-gallate (Standard)	Structural Classification Flavonoids Flavanols Phenols Polyphenols Camellia sinensis (L.) O. Ktze. Plants Source Classification Theaceae	Reference Standards Apoptosis MDM-2/p53 ATM/ATR Checkpoint Kinase (Chk)
Theaflavin-3-gallate (Standard) is the analytical standard of Theaflavin-3-gallate. This product is intended for research and analytical applications. Theaflavin-3-gallate, a black tea theaflavin monomer, is regarded as the biologically important active component of black tea and provides health benefits. Theaflavin-3-gallate acts as prooxidants and induces oxidative stress in the carcinoma cells. Theaflavin-3-gallate reacts directly with reduced glutathione (GSH) in a time- and concentration-dependent manner. Theaflavin-3-gallate induces apoptosis and G1 cell cycle arrest in ovarian cancer A2780/CP70 cells through p53-dependent pathways. Theaflavin-3-gallate induces DNA damage through *ATM/Chk/p53* pathway .

HY-N18301

Americanin A	Structural Classification Monophenols Phenols Plants Phytolacca americana L. Phytolaccaceae Source Classification	ATM/ATR Checkpoint Kinase (Chk) MDM-2/p53 E1/E2/E3 Enzyme CDK Mitosis Reactive Oxygen Species (ROS) Apoptosis
Americanin A is a Neolignan. Americanin A can be isolated from the seeds of Phytolacca americana. Americanin A activates *ATM* and ATR, initiating the subsequent signal transduction cascades that include Chk1, Chk2, and tumor suppressor p53. Americanin A targets selectively Skp2 for degradation and thereby stabilizes p27. Americanin A suppresses the activity of Cyclin B1 and its partner cdc2 to prevent entry into Mitosis. Americanin A induces Apoptosis by producing excessive ROS. Americanin A has anti-cancer activity against colorectal cancer .

Cat. No.	Product Name	Chemical Structure

HY-W766548

Floxuridine-13C,15N2

Floxuridine- ¹³C, ¹⁵N₂ (5-Fluorouracil 2'-deoxyriboside- ¹³C, ¹⁵N₂) is the ¹³C- and ¹⁵N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis . Floxuridine has antiviral effects against HSV and CMV .

Host:	Mouse (3) Rabbit (8)
Reactivity:	Human (11) Rat (4) Mouse (4) Monkey (2)
Application:	IHC-P (6) ICC/IF (10) CHIP (1) IP (7) Cut&Tag (1) WB (9) FC (3) ELISA (5)
Isotype:	IgG (7) IgG, Kappa (1) IgG2b (2)
Conjugation:	Non-conjugated (11)
Clonality:	Monoclonal (9) Recombinant (5)
Modification:	Phosphorylated (3) Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86109

	ATM Antibody (YA5801) Atm; Serine-protein kinase Atm; Ataxia telangiectasia mutated; A-T mutated	WB, ICC/IF, IP, ELISA	Human, Mouse, Rat
	ATM Antibody (YA5801) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATM.

HY-P85049

	ATM Antibody (YA4741) Atm; Serine-protein kinase Atm; Ataxia telangiectasia mutated; A-T mutated	WB, ELISA	Human
	ATM Antibody (YA4741) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ATM.

HY-P83436

	*Phospho-ATM* (Ser1981) Antibody (YA3181)** Atm; Serine-protein kinase Atm; Ataxia telangiectasia mutated; A-T mutated	WB, IHC-P, ICC/IF, IP	Human
	Phospho-ATM (Ser1981) Antibody (YA3181) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-ATM (Ser1981).

HY-P80023

	ATM Antibody (YA597)	WB, ICC/IF, IHC-P	Human
	ATM Antibody (YA597) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ATM.

HY-P80453

	*Phospho-ATM* (S1981) Antibody (YA223)**	WB, ICC/IF, IHC-P, IP	Human
	Phospho-ATM (S1981) Antibody (YA223) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-ATM (S1981).

HY-P87805

	*Phospho-ATM* (Ser1981) Antibody (YA7490)**	WB, IHC-P, ICC/IF, IP, ELISA, CHIP, Cut&Tag	Human, Mouse, Rat
	Phospho-ATM (Ser1981) Antibody (YA7490) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to Phospho-ATM (Ser1981).

HY-P82549

	BRAT1 Antibody (YA2294) BRCA1-associated Atm activator 1; BRCA1-associated protein required for Atm activation protein 1	WB, ICC/IF, IP	Human
	BRAT1 Antibody (YA2294) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRAT1.

HY-P82549A

	BRAT1 Antibody (YA2294)(PBS only) BRCA1-associated Atm activator 1; BRCA1-associated protein required for Atm activation protein 1	WB, ICC/IF, IP	Human
	BRAT1 Antibody (YA2294) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRAT1.

HY-P86288

	BRAT1 Antibody (YA5980) BRAT1; BAAT1; C7orf27; BRCA1-associated Atm activator 1 ; BRCA1-associated protein required for Atm activation protein 1;	WB, ICC/IF, FC, IP	Human
	BRAT1 Antibody (YA5980) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BRAT1.

HY-P84535

	ATM Antibody (YA4232) AT1; ATA; ATC; ATD; ATE; ATDC; TEL1; TELO1	IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Monkey, Rat
	ATM Antibody (YA4232) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to ATM.

HY-P84535A

	ATM Antibody (YA4232)(PBS only) AT1; ATA; ATC; ATD; ATE; ATDC; TEL1; TELO1	IHC-P, ICC/IF, FC, ELISA	Human, Mouse, Monkey, Rat
	ATM Antibody (YA4232) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to ATM.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks